Trial Profile
Pivotal phase 3, registration study of MAT2203 for the prevention of invasive fungal infections (IFIs) in patients on immunosuppressive therapy while receiving chemotherapy for hematologic malignancies
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 28 Sep 2023
Price :
$35
*
At a glance
- Drugs Amphotericin B (Primary)
- Indications Mycoses
- Focus Registrational; Therapeutic Use
- Sponsors Matinas BioPharma
- 27 Sep 2023 According to a Matinas BioPharma media release, company announced that MAT2203 oral LNC formulation will be featured in an oral company pipeline presentation at IDWeek, being held October 11-15 at the Boston Convention and Exhibition Center.
- 15 Mar 2023 According to a Matinas BioPharma media release, company will have a planned meeting with FDA to discuss safety, efficacy, and tolerability of oral MAT2203 and feedback from this meeting will be instrumental in guiding efforts to secure non-dilutive funding from Biomedical Advanced Research and Development Authority (BARDA) and/or the National Institutes of Health (NIH), as well as in advancing ongoing discussions with potential partners for further development of MAT2203.
- 15 Mar 2023 According to a Matinas BioPharma media release, company to seek guidance from US FDA for this study for treatment of invasive fungal infections.